Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C D Furberg

Showing results (91-100 of 205) with videos related to

Pageof 21
Sort By:
Current Problems in Cardiology|June 1, 1984
The use of beta-adrenergic blocking drugs in patients with myocardial infarctionW H Frishman, C D Furberg, W T Friedewald
Hypertension (Dallas, Tex. : 1979)|May 1, 1989
Controlled clinical trials of drug treatment for hypertension. A reviewJ A Cutler, S W MacMahon, C D Furberg
Ultrasound in Medicine & Biology|January 1, 1996
Assessment of temporal bias in longitudinal measurements of carotid intimal-medial thickness in the Asymptomatic Carotid Artery Progression Study (ACAPS). ACAPS Research GroupW A Riley, T Craven, A Romont, et al.
The American Journal of Cardiology|June 1, 1990
Propranolol-induced lipid changes and their prognostic significance after a myocardial infarction: the Beta-Blocker Heart Attack Trial experienceR P Byington, J Worthy, T Craven, et al.
Lancet (London, England)|April 23, 1999
Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular eventsR P Byington, T E Craven, C D Furberg, et al.
Journal of Internal Medicine|May 1, 1994
Overtreatment and undertreatment of hypertensionC D Furberg, G Berglund, T A Manolio, et al.
American Journal of Hypertension|June 20, 1998
Cost-minimization and the number needed to treat in uncomplicated hypertensionK A Pearce, C D Furberg, B M Psaty, et al.
Archives of Internal Medicine|February 11, 2000
Sex bias and underutilization of lipid-lowering therapy in patients with coronary artery disease at academic medical centers in the United States and Canada. Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT) InvestigatorsM Miller, R Byington, D Hunninghake, et al.
BMJ (Clinical Research Ed.)|April 7, 1990
Long term propranolol treatment and changes in body weight after myocardial infarctionS Rössner, C L Taylor, R P Byington, et al.
JAMA|January 22, 1997
The Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS)W B Applegate, C D Furberg, R P Byington, et al.
Pageof 21

Showing results (91-100 of 205) with videos related to

Sort By:
Pageof 21
Current Problems in Cardiology|June 1, 1984
The use of beta-adrenergic blocking drugs in patients with myocardial infarctionW H Frishman, C D Furberg, W T Friedewald
Hypertension (Dallas, Tex. : 1979)|May 1, 1989
Controlled clinical trials of drug treatment for hypertension. A reviewJ A Cutler, S W MacMahon, C D Furberg
Ultrasound in Medicine & Biology|January 1, 1996
Assessment of temporal bias in longitudinal measurements of carotid intimal-medial thickness in the Asymptomatic Carotid Artery Progression Study (ACAPS). ACAPS Research GroupW A Riley, T Craven, A Romont, et al.
The American Journal of Cardiology|June 1, 1990
Propranolol-induced lipid changes and their prognostic significance after a myocardial infarction: the Beta-Blocker Heart Attack Trial experienceR P Byington, J Worthy, T Craven, et al.
Lancet (London, England)|April 23, 1999
Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular eventsR P Byington, T E Craven, C D Furberg, et al.
Journal of Internal Medicine|May 1, 1994
Overtreatment and undertreatment of hypertensionC D Furberg, G Berglund, T A Manolio, et al.
American Journal of Hypertension|June 20, 1998
Cost-minimization and the number needed to treat in uncomplicated hypertensionK A Pearce, C D Furberg, B M Psaty, et al.
Archives of Internal Medicine|February 11, 2000
Sex bias and underutilization of lipid-lowering therapy in patients with coronary artery disease at academic medical centers in the United States and Canada. Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT) InvestigatorsM Miller, R Byington, D Hunninghake, et al.
BMJ (Clinical Research Ed.)|April 7, 1990
Long term propranolol treatment and changes in body weight after myocardial infarctionS Rössner, C L Taylor, R P Byington, et al.
JAMA|January 22, 1997
The Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS)W B Applegate, C D Furberg, R P Byington, et al.
Pageof 21